2012-10-24 16:03:47 - CF101 (Dry Eye Syndrome) - Analysis and Forecasts to 2022 - a new market research report on companiesandmarkets.com

CF101 (Dry Eye Syndrome) - Analysis and Forecasts to 2022 - This pharmaceuticals report, "CF101 (Dry Eye Syndrome) - Analysis and Forecasts to 2022" provides CF101 sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2022). The report also includes information on Dry Eye Syndrome. This report is built using data and information sourced from our proprietary databases, primary and secondary research using Company´s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by our team of industry experts.

Scope

- Therapy area profile including patient

 

 

population for the US and EU5.
- Analysis and review of CF101 including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of CF101 Liquid including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2022 for CF101 in the US and EU5

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug´s performance
- Examine the historical sales performance of a drug in six major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2013-2022 for all six major markets

Keywords

CF101,IB-MECA,Can-Fite Biopharma,Phase III,dry eye syndrome,oral formulation,anti inflammatory agent ,

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.